|
1
|
Ilic N, Petricevic A, Arar D, Kotarac S,
Banovic J, Ilic NF, Tripkovic A and Grandic L: Skip mediastinal
nodal metastases in the IIIa/N2 non-small cell lung cancer. J
Thorac Oncol. 2:1018–1021. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Siegel R, Ma J, Zou Z and Jemal A: Cancer
statistics, 2014. CA Cancer J Clin. 64:9–29. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2015. CA Cancer J Clin. 65:5–29. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Boffetta P and Nyberg F: Contribution of
environmental factors to cancer risk. Br Med Bull. 68:71–94. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Didkowska J, Manczuk M, McNeill A, Powles
J and Zatonski W: Lung cancer mortality at ages 35–54 in the
European Union: Ecological study of evolving tobacco epidemics.
BMJ. 331:189–191. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Ridge CA, McErlean AM and Ginsberg MS:
Epidemiology of lung cancer. Semin Intervent Radiol. 30:93–98.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Paliogiannis P, Attene F, Cossu A, Budroni
M, Cesaraccio R, Tanda F, Trignano M and Palmieri G: Lung cancer
epidemiology in North Sardinia, Italy. Multidiscip Respir Med.
8:452013. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Ni T, Mao G, Xue Q, Liu Y, Chen B, Cui X,
Lv L, Jia L, Wang Y and Ji L: Upregulated expression of ILF2 in
non-small cell lung cancer is associated with tumor cell
proliferation and poor prognosis. J Mol Histol. 46:325–335. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Peters S, Adjei AA, Gridelli C, Reck M,
Kerr K and Felip E: ESMO Guidelines Working Group: Metastatic
non-small-cell lung cancer (NSCLC): ESMO clinical practice
guidelines for diagnosis, treatment and follow-up. Ann Oncol.
23:(Suppl 7). vii56–vii64. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Zhang T, Zhang DM, Zhao D, Hou XM, Liu XJ,
Ling XL and Ma SC: The prognostic value of osteopontin expression
in non-small cell lung cancer: A meta-analysis. J Mol Histol.
45:533–540. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Cai J, Fang L, Huang Y, Li R, Yuan J, Yang
Y, Zhu X, Chen B, Wu J and Li M: miR-205 targets PTEN and PHLPP2 to
augment AKT signaling and drive malignant phenotypes in non-small
cell lung cancer. Cancer Res. 73:5402–5415. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Pisters KM, Evans WK, Azzoli CG, Kris MG,
Smith CA, Desch CE, Somerfield MR, Brouwers MC, Darling G, Ellis
PM, et al: Cancer care ontario and American society of clinical
oncology adjuvant chemotherapy and adjuvant radiation therapy for
stages I-IIIA resectable non small-cell lung cancer guideline. J
Clin Oncol. 25:5506–5518. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Verdecchia A, Francisci S, Brenner H,
Gatta G, Micheli A, Mangone L and Kunkler I: EUROCARE-4 Working
Group: Recent cancer survival in Europe: A 2000–02 period analysis
of EUROCARE-4 data. Lancet Oncol. 8:784–796. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Sun W, Yuan X, Tian Y, Wu H, Xu H, Hu G
and Wu K: Non-invasive approaches to monitor EGFR-TKI treatment in
non-small-cell lung cancer. J Hematol Oncol. 8:952015. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Liu R, Liu X, Zheng Y, Gu J, Xiong S,
Jiang P, Jiang X, Huang E, Yang Y, Ge D and Chu Y: MicroRNA-7
sensitizes non-small cell lung cancer cells to paclitaxel. Oncol
Lett. 8:2193–2200. 2014.PubMed/NCBI
|
|
16
|
Ma Y, Li X, Cheng S, Wei W and Li Y:
MicroRNA-106a confers cisplatin resistance in non-small cell lung
cancer A549 cells by targeting adenosine triphosphatase-binding
cassette A1. Mol Med Rep. 11:625–632. 2015.PubMed/NCBI
|
|
17
|
Zhong Z, Xia Y, Wang P, Liu B and Chen Y:
Low expression of microRNA-30c promotes invasion by inducing
epithelial mesenchymal transition in non-small cell lung cancer.
Mol Med Rep. 10:2575–2579. 2014.PubMed/NCBI
|
|
18
|
Shi Y, Liu C, Liu X, Tang DG and Wang J:
The microRNA miR-34a inhibits non-small cell lung cancer (NSCLC)
growth and the CD44hi stem-like NSCLC cells. PLoS One.
9:e900222014. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Li X, Abdel-Mageed AB, Mondal D and Kandil
E: MicroRNA expression profiles in differentiated thyroid cancer, a
review. Int J Clin Exp Med. 6:74–80. 2013.PubMed/NCBI
|
|
20
|
Hwang HW and Mendell JT: MicroRNAs in cell
proliferation, cell death, and tumorigenesis. Br J Cancer.
96:(Suppl). R40–R44. 2007.PubMed/NCBI
|
|
21
|
Tafsiri E, Darbouy M, Shadmehr MB,
Zagryazhskaya A, Alizadeh J and Karimipoor M: Expression of miRNAs
in non-small-cell lung carcinomas and their association with
clinicopathological features. Tumour Biol. 36:1603–1612. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Braun J and Hüttelmaier S: Pathogenic
mechanisms of deregulated microRNA expression in thyroid carcinomas
of follicular origin. Thyroid Res. 4:(Suppl 1). S12011. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Zhang B, Pan X, Cobb GP and Anderson TA:
microRNAs as oncogenes and tumor suppressors. Dev Biol. 302:1–12.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Esquela-Kerscher A and Slack FJ:
Oncomirs-microRNAs with a role in cancer. Nat Rev Cancer.
6:259–269. 2006. View
Article : Google Scholar : PubMed/NCBI
|
|
25
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−Delta Delta C(T)) Method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Kriegel AJ, Liu Y, Fang Y, Ding X and
Liang M: The miR-29 family: Genomics, cell biology, and relevance
to renal and cardiovascular injury. Physiol Genomics. 44:237–244.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Wang Y, Zhang X, Li H, Yu J and Ren X: The
role of miRNA-29 family in cancer. Eur J Cell Biol. 92:123–128.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Li J, Wan X, Qiang W, Li T, Huang W, Huang
S, Wu D and Li Y: MiR-29a suppresses prostate cell proliferation
and induces apoptosis via KDM5B protein regulation. Int J Clin Exp
Med. 8:5329–5339. 2015.PubMed/NCBI
|
|
29
|
Liu X, Cai J, Sun Y, Gong R, Sun D, Zhong
X, Jiang S, He X, Bao E, Yang L and Li Y: MicroRNA-29a inhibits
cell migration and invasion via targeting Roundabout homolog 1 in
gastric cancer cells. Mol Med Rep. 12:3944–3950. 2015.PubMed/NCBI
|
|
30
|
Liu C, Duan P, Li B, Huang C, Jing Y and
Yan W: miR-29a activates Hes1 by targeting Nfia in esophageal
carcinoma cell line TE-1. Oncol Lett. 9:96–102. 2015.PubMed/NCBI
|
|
31
|
Wang F, Wang XS, Yang GH, Zhai PF, Xiao Z,
Xia LY, Chen LR, Wang Y, Wang XZ, Bi LX, et al: miR-29a and
miR-142-3p downregulation and diagnostic implication in human acute
myeloid leukemia. Mol Biol Rep. 39:2713–2722. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Zhu XC, Dong QZ, Zhang XF, Deng B, Jia HL,
Ye QH, Qin LX and Wu XZ: microRNA-29a suppresses cell proliferation
by targeting SPARC in hepatocellular carcinoma. Int J Mol Med.
30:1321–1326. 2012.PubMed/NCBI
|
|
33
|
Tang W, Zhu Y, Gao J, Fu J, Liu C, Liu Y,
Song C, Zhu S, Leng Y, Wang G, et al: MicroRNA-29a promotes
colorectal cancer metastasis by regulating matrix metalloproteinase
2 and E-cadherin via KLF4. Br J Cancer. 110:450–458. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Nishikawa R, Chiyomaru T, Enokida H,
Inoguchi S, Ishihara T, Matsushita R, Goto Y, Fukumoto I, Nakagawa
M and Seki N: Tumour-suppressive microRNA-29s directly regulate
LOXL2 expression and inhibit cancer cell migration and invasion in
renal cell carcinoma. FEBS Lett. 589:2136–2145. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Tréhoux S, Lahdaoui F, Delpu Y, Renaud F,
Leteurtre E, Torrisani J, Jonckheere N and Van Seuningen I:
Micro-RNAs miR-29a and miR-330-5p function as tumor suppressors by
targeting the MUC1 mucin in pancreatic cancer cells. Biochim
Biophys Acta. 1853:2392–2403. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Zhao Z, Wang L, Song W, Cui H, Chen G,
Qiao F, Hu J, Zhou R and Fan H: Reduced miR-29a-3p expression is
linked to the cell proliferation and cell migration in gastric
cancer. World J Surg Oncol. 13:1012015. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Lu L, Xue X, Lan J, Gao Y, Xiong Z, Zhang
H, Jiang W, Song W and Zhi Q: MicroRNA-29a upregulates MMP2 in oral
squamous cell carcinoma to promote cancer invasion and
anti-apoptosis. Biomed Pharmacother. 68:13–19. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Ma J, Xue Y, Liu W, Yue C, Bi F, Xu J,
Zhang J, Li Y, Zhong C and Chen Y: Role of activated Rac1/Cdc42 in
mediating endothelial cell proliferation and tumor angiogenesis in
breast cancer. PLoS One. 8:e662752013. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Sun N, Ye L, Chang T and Li X and Li X:
microRNA-195-Cdc42 axis acts as a prognostic factor of esophageal
squamous cell carcinoma. Int J Clin Exp Pathol. 7:6871–6879.
2014.PubMed/NCBI
|
|
40
|
Reymond N, Im JH, Garg R, Vega FM, Borda
d'Agua B, Riou P, Cox S, Valderrama F, Muschel RJ and Ridley AJ:
Cdc42 promotes transendothelial migration of cancer cells through
β1 integrin. J Cell Biol. 199:653–668. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Stengel KR and Zheng Y: Essential role of
Cdc42 in Ras-induced transformation revealed by gene targeting.
PLoS One. 7:e373172012. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Nobes CD and Hall A: Rho, rac and cdc42
GTPases regulate the assembly of multimolecular focal complexes
associated with actin stress fibers, lamellipodia, and filopodia.
Cell. 81:53–62. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Olson MF, Ashworth A and Hall A: An
essential role for Rho, Rac and Cdc42 GTPases in cell cycle
progression through G1. Science. 269:1270–1272. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Chen QY, Jiao DM, Yao QH, Yan J, Song J,
Chen FY, Lu GH and Zhou JY: Expression analysis of Cdc42 in lung
cancer and modulation of its expression by curcumin in lung cancer
cell lines. Int J Oncol. 40:1561–1568. 2012.PubMed/NCBI
|
|
45
|
Liu M, Lang N, Qiu M, Xu F, Li Q, Tang Q,
Chen J, Chen X, Zhang S, Liu Z, et al: miR-137 targets Cdc42
expression, induces cell cycle G1 arrest and inhibits invasion in
colorectal cancer cells. Int J Cancer. 128:1269–1279. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Humphreys KJ, McKinnon RA and Michael MZ:
miR-18a inhibits CDC42 and plays a tumour suppressor role in
colorectal cancer cells. PLoS One. 9:e1122882014. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Ke TW, Hsu HL, Wu YH, Chen WT, Cheng YW
and Cheng CW: MicroRNA-224 suppresses colorectal cancer cell
migration by targeting Cdc42. Dis Markers. 2014:6171502014.
View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Fu MG, Li S, Yu TT, Qian LJ, Cao RS, Zhu
H, Xiao B, Jiao CH, Tang NN, Ma JJ, et al: Differential expression
of miR-195 in esophageal squamous cell carcinoma and miR-195
expression inhibits tumor cell proliferation and invasion by
targeting of Cdc42. FEBS Lett. 587:3471–3479. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Zhang Y, Takahashi S, Tasaka A, Yoshima T,
Ochi H and Chayama K: Involvement of microRNA-224 in cell
proliferation, migration, invasion, and anti-apoptosis in
hepatocellular carcinoma. J Gastroenterol Hepatol. 28:565–575.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Chen Q, Chen X, Zhang M, Fan Q, Luo S and
Cao X: miR-137 is frequently down-regulated in gastric cancer and
is a negative regulator of Cdc42. Dig Dis Sci. 56:2009–2016. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Yang T, Chen T, Li Y, Gao L, Zhang S, Wang
T and Chen M: Downregulation of miR-25 modulates non-small cell
lung cancer cells by targeting CDC42. Tumour Biol. 36:1903–1911.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Zhu X, Li Y, Shen H, Li H, Long L, Hui L
and Xu W: miR-137 inhibits the proliferation of lung cancer cells
by targeting Cdc42 and Cdk6. FEBS Lett. 587:73–81. 2013. View Article : Google Scholar : PubMed/NCBI
|
